PEART (Percutaneous Endovascular Arch Repair Trial) Study.
Study Details
Study Description
Brief Summary
This study is the feasible study on a new technique of of ZIPPER aortic arch stentgraft system
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The feasible study of ZIPPER aortic arch stentgraft system is a prospective, multicenter, single arm trial, which will enroll a total of 12 patients. The goal of this study is to evaluate the safety and efficacy of ZIPPER aortic arch stentgraft system in the treatment of patients with aortic dissections
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: ZIPPER aortic arch stentgraft system
|
Device: ZIPPER aortic arch stentgraft system
The ZIPPER aortic arch stentgraft system consists of the arch mainbody stentgraft system, the branch artery stentgraft system and the thoracic extension stentgraft system.
|
Outcome Measures
Primary Outcome Measures
- Freedom from major device/procedure-related adverse events within 30 days post-operation. [30 days after intervention]
Device or procedure related major adverse events included: stroke, respiratory failure, pericardial tamponade, dissection or aneurysm rupture, paraplegia, stent occlusion, fracture, migration, access vessel thrombosis or rupture, conversion to open surgery, death.
Secondary Outcome Measures
- Immediate postoperative technical success. [immediately after intervention]
Immediate technical success is defined as successful delivery of the aortic and branching stent graft conveyors to their predetermined positions, accurate positioning and successful deployment of the stent, safe removal of the delivery device outside the body, absence of Type I and III endoleaks on angiography at the end of the procedure , and patent branch stents.
- Incidence of Type I or Type III endoleaks. [1 month, 6 months and 12 months post-intervention]
Endoleak evaluated by DSA or CTA during operation and at 1 month, 6 months and 12 months after operation. Intraoperative endoleaks that were treated with adjuvant therapy were not documented. Endoleaks occurring in the same subject after completion of the procedure, and that were not treated at different visits, are counted as once.
- Incidence of aortic arch stent graft migration. [1 month, 6 months and 12 months post-intervention]
CTA will be performed at 1, 6, and 12 months after operation to determine if the stent has migrated, and evaluations will be recorded for both the main and branch stents. Migration is defined as the main and branched stents migrate more than 10 mm at postoperative follow-up compared with that 1 month post-intervention.
- Postoperative branch vessel patency rate. [1 month, 6 months and 12 months post-intervention]
CTA examinations will be performed at 1, 6, and 12 months post-operation to evaluate branch vessel revascularization and whether there is occlusion, stenosis, or stent thrombosis.
- Results of aortic remodeling after aortic dissection surgery [1 month, 6 months and 12 months post-intervention]
CTA examinations will be performed at 1, 6, and 12 months post-operation to evaluate results of aortic remodeling, including the expansion of the true lumen and the thrombosis of the false lumen at the coverage of the aortic dissection vascular stent to determine whether the blood vessel is successfully remodeled.
- Incidence of surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention. [within 12 months post-intervention]
Whether or not the patient experienced surgically induced de novo aortic dissection converted to open-heart surgery or secondary intervention will be determined.
- Aortic-related mortality at 12 months post operation. [within 12 months post-intervention]
Refers to death caused by aortic rupture or endovascular treatment.
- All-cause mortality and major stroke within 12 months post-procedure. [within 12 months post-intervention]
All-cause mortality includes cardiac death, non-cardiac death, and unexpected death. Major stroke is defined as a modified Rankin score (mRS) ≥ 2 at 90 days after stroke onset.
- Incidence of severe adverse events. [within 12 months post-intervention]
Refers to an event that occurs during the clinical trial that results in mortality or serious deterioration in patient health, including a fatal illness or injury, a permanent defect in body structure or body function, or an event that requires medical or surgical intervention to avoid one or more permanent defects in body structure or body function.
- Incidence of device-related adverse events. [within 12 months post-intervention]
Device-related adverse event refers to an adverse medical event related to the use of test device during the clinical trial. However, a distinction should be made with respect to normal postoperative stress response, such as fever and chest and back discomfort, which, in the judgment of the investigator, need not be recorded as an adverse event.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients aged 18 to 80 years old
-
Patients diagnosed with aortic dissections requiring intervention, including non-A-non-B aortic dissection, or residual dissection after type A ascending aortic repair;.
-
Patients with suitable vascular conditions, including:
-
Ascending aorta (including surgical graft) length greater than 30 mm (from the aortic sinusoid junction to the proximal cardiac margin of the innominate artery).
-
Proximal anchoring zone diameter ≥ 24 mm and ≤ 47 mm;
-
Proximal anchoring zone length ≥ 20 mm;
-
Innominate artery, left common carotid artery and left subclavian artery diameter ≤ 24 mm and ≥ 7 mm, length ≥ 20 mm；
-
Suitable arterial access for endovascular interventional treatment;
-
Patients able to understand the purpose of the trial, participate in the trial voluntarily with informed consent form signed by the subject him/herself or his or her legal representative, and willing to complete follow-up visits as required under the protocol.
-
Evaluated by at least two investigators that the subjects are high-risk patients with more complications, poor general condition, high risk of deep hypothermic circulatory arrest, and not suitable for total arch replacement and other surgical procedures.
Exclusion Criteria:
-
Previously received open surgery or endovascular intervention for descending aorta or abdominal aorta;
-
Infectious aortic disease, takayasu arteritis, Marfan syndrome (or other connective tissue diseases );
-
Patients that have experienced systemic infection within past three months;
-
Neck surgery was performed within past three months;
-
Patients with severe stenosis, calcification, thrombosis or tortuosity in the brachiocephalic trunk, left common carotid artery or left subclavian artery;
-
Patients with intestinal necrosis and lower limb ischemic necrosis;
-
Paraplegic patients;
-
Heart transplant patients;
-
Patients that have suffered MI or stroke within past three months;
-
Patients with Class IV heart function (NYHA classification) or LVEF<30%
-
Active peptic ulcers or upper gastrointestinal bleeding occurring within the past three months;
-
Hematological abnormality, defined as follows: Leukopenia (WBC < 3 × 109/L), anemia (Hb < 90 g/L); coagulation dysfunction, thrombocytopenia (PLT count< 50 × 109/L);
-
Patients with renal insufficiency， serum creatinine > 150 umol/L (or 3.0 mg/dl) and / or end-stage renal disease requiring dialysis, shall be determined by the investigator after a comprehensive analysis;
-
Patients with severe liver dysfunction: ALT or AST exceeding 3 times the upper limit of norma, serum total bilirubin (STB) exceeds 2 times the upper limit of normal;
-
Patients who are allergic to contrast agents;
-
Patients that are pregnant or breastfeeding;
-
Patients with severe comorbidities who cannot tolerate anesthesia and surgery;
-
Patients with a life expectancy of less than 12 months;
-
Patients currently participating in other drug or device study;
-
The investigator assessed that the patient was ineligible for the study for other diseases or abnormalities.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Jia Hu | Chengdu | China | ||
| 2 | Weiguo Fu | Shanghai | China | ||
| 3 | Honglin Dong | Taiyuan | China |
Sponsors and Collaborators
- Hangzhou Endonom Medtech Co., Ltd.
Investigators
- Principal Investigator: Weiguo Fu, Fudan University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ZIPPER V1.0